Article ; Online: Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Hematology (Amsterdam, Netherlands)
2020 Volume 25, Issue 1, Page(s) 327–334
Abstract: Objectives: ...
Abstract | Objectives: |
---|---|
MeSH term(s) | Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Complement Inactivating Agents/economics ; Complement Inactivating Agents/therapeutic use ; Cost of Illness ; Hemoglobinuria, Paroxysmal/drug therapy ; Hemoglobinuria, Paroxysmal/economics ; Hemoglobinuria, Paroxysmal/pathology ; Hemolysis/drug effects ; Humans ; Patient Acceptance of Health Care |
Chemical Substances | Antibodies, Monoclonal, Humanized ; Complement Inactivating Agents ; eculizumab (A3ULP0F556) ; ravulizumab (C3VX249T6L) |
Language | English |
Publishing date | 2020-08-27 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 1341428-8 |
ISSN | 1607-8454 ; 1024-5332 ; 1024-5340 |
ISSN (online) | 1607-8454 |
ISSN | 1024-5332 ; 1024-5340 |
DOI | 10.1080/16078454.2020.1807226 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4538: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.